|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
207,851,000 |
Market
Cap: |
11.51(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$32.14 - $59.82 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
387 |
387 |
11,063 |
116,582 |
Total Sell Value |
$21,749 |
$21,749 |
$512,581 |
$11,151,362 |
Total People Sold |
1 |
1 |
12 |
18 |
Total Sell Transactions |
1 |
1 |
25 |
69 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Whitlow Ricci S |
President, CSS |
|
2020-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,464 |
2,464 |
|
- |
|
Grippo Michael J |
SVP, Strategy & Corp. Dev. |
|
2020-01-13 |
4 |
AS |
$58.00 |
$97,440 |
D/D |
(1,680) |
11,647 |
|
32% |
|
Flynn Karen |
Pres. Biologics & CCO |
|
2020-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
35,286 |
35,286 |
|
- |
|
Grippo Michael J |
SVP, Strategy & Corp. Dev. |
|
2019-12-20 |
4 |
AS |
$56.00 |
$134,736 |
D/D |
(2,406) |
13,327 |
|
- |
|
Grippo Michael J |
SVP, Strategy & Corp. Dev. |
|
2019-12-19 |
4 |
AS |
$54.00 |
$99,684 |
D/D |
(1,846) |
15,733 |
|
- |
|
Maselli Alessandro |
President & COO |
|
2019-12-16 |
4 |
AS |
$53.18 |
$386,512 |
D/D |
(7,268) |
12,802 |
|
- |
|
Chiminski John R |
Chair & CEO |
|
2019-12-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
9,650 |
214,607 |
|
- |
|
Pravda Ricardo |
SVP & Chief HR Officer |
|
2019-11-26 |
4 |
S |
$52.71 |
$137,718 |
D/D |
(2,612) |
10,846 |
|
- |
|
Gennadios Aristippos |
President Softgel & Oral Tech |
|
2019-11-25 |
4 |
AS |
$52.55 |
$2,378,203 |
D/D |
(45,256) |
44,241 |
|
- |
|
Gennadios Aristippos |
President Softgel & Oral Tech |
|
2019-11-25 |
4 |
D |
$52.55 |
$4,131,218 |
D/D |
(78,615) |
89,497 |
|
- |
|
Gennadios Aristippos |
President Softgel & Oral Tech |
|
2019-11-25 |
4 |
OE |
$12.14 |
$2,272,760 |
D/D |
123,880 |
100,355 |
|
- |
|
Grippo Michael J |
SVP, Strategy & Corp. Dev. |
|
2019-11-22 |
4 |
AS |
$52.00 |
$19,552 |
D/D |
(376) |
10,702 |
|
- |
|
Grippo Michael J |
SVP, Strategy & Corp. Dev.Offi |
|
2019-10-30 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
16,026 |
|
- |
|
Grippo Michael J |
SVP, Strategy & Corp. Dev.Offi |
|
2019-10-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,078 |
|
- |
|
Chiminski John R |
Chair & CEO |
|
2019-10-07 |
4 |
AS |
$48.84 |
$4,739,580 |
D/D |
(97,043) |
224,257 |
|
- |
|
Chiminski John R |
Chair & CEO |
|
2019-10-07 |
4 |
D |
$48.84 |
$1,664,907 |
D/D |
(34,089) |
321,300 |
|
- |
|
Chiminski John R |
Chair & CEO |
|
2019-10-07 |
4 |
OE |
$24.26 |
$1,160,409 |
D/D |
47,552 |
348,387 |
|
- |
|
Lucier Gregory T |
Director |
|
2019-09-09 |
4 |
B |
$51.64 |
$103,280 |
D/D |
2,000 |
38,921 |
2.39 |
- |
|
Maselli Alessandro |
President & COO |
|
2019-09-09 |
4 |
D |
$52.48 |
$173,132 |
D/D |
(3,299) |
20,070 |
|
- |
|
Lucier Gregory T |
Director |
|
2019-09-05 |
4 |
GA |
$0.00 |
$0 |
I/I |
5,068 |
5,068 |
|
- |
|
Lucier Gregory T |
Director |
|
2019-09-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,068 |
36,921 |
|
- |
|
Kreuzburg Christa |
Director |
|
2019-08-23 |
4 |
D |
$53.15 |
$66,703 |
D/D |
(1,255) |
6,930 |
|
- |
|
Zippelius Peter |
Director |
|
2019-08-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,167 |
3,642 |
|
- |
|
Gennadios Aristippos |
President, Softgel Tech. |
|
2019-08-22 |
4 |
D |
$55.24 |
$210,188 |
D/D |
(3,805) |
44,232 |
|
- |
|
Gennadios Aristippos |
President, Softgel Tech. |
|
2019-08-22 |
4 |
A |
$0.00 |
$0 |
D/D |
12,420 |
48,037 |
|
- |
|
821 Records found
|
|
Page 18 of 33 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|